On the other hand, we previously reported that β-catenin in DCs also played a positive role in the maintenance of DC vaccine-induced CD8 T cell memory responses [22], suggesting that β-catenin might not be an ideal therapeutic target to boost anti-tumor CD8 T cell immunity. This evidence concerns the gene CD8A and neoplasm.